Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTC-based Relapse Prediction and Adjuvant Therapy in Resectable NSCLC
NCT06262386Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in non-small cell lung cancer (NSCLC), sponsored by Chang Gung Memorial Hospital. Primary endpoints: Accuracy of proposed relapse prediction model and early relapse rate. Started Aug 2023; status: recruiting.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06262386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262386.